CA2373994A1 - Excipient en emulsion pour medicaments faiblement solubles - Google Patents

Excipient en emulsion pour medicaments faiblement solubles Download PDF

Info

Publication number
CA2373994A1
CA2373994A1 CA002373994A CA2373994A CA2373994A1 CA 2373994 A1 CA2373994 A1 CA 2373994A1 CA 002373994 A CA002373994 A CA 002373994A CA 2373994 A CA2373994 A CA 2373994A CA 2373994 A1 CA2373994 A1 CA 2373994A1
Authority
CA
Canada
Prior art keywords
paclitaxel
composition according
tocopherol
emulsion
tpgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373994A
Other languages
English (en)
Inventor
Karel J. Lambert
Panayiotis P. Constantinides
Steven C. Quay
Alexander K. Tustian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sonus Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/317,499 external-priority patent/US6660286B1/en
Application filed by Individual filed Critical Individual
Publication of CA2373994A1 publication Critical patent/CA2373994A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à une émulsion comportant un ou plusieurs tocols et un co-solvant et stabilisée par des tensioactifs biocompatibles, qui est utilisée en tant qu'excipient ou support de médicaments thérapeutiques. Cette émulsion ne contient pratiquement pas d'éthanol et elle peut être administrée à des animaux ou des humains selon différentes voies. Ladite émulsion comporte également de la vitamine E associée à du polyéthylène glycol (PEG). Le .alpha.-tocophérol associé à du PEG comporte des sous-unités de polyéthylène glycol reliées par un diester d'acide succinique au noyau hydroxyle de la vitamine E et il sert de tensioactif primaire, de stabilisateur et de solvant secondaire dans les émulsions de tocol.
CA002373994A 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles Abandoned CA2373994A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31749599A 1999-05-24 1999-05-24
US09/317,495 1999-05-24
US09/317,499 1999-05-24
US09/317,499 US6660286B1 (en) 1997-01-07 1999-05-24 Emulsion vehicle for poorly soluble drugs
US15612899P 1999-09-27 1999-09-27
US60/156,128 1999-09-27
PCT/US2000/013572 WO2000071163A1 (fr) 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles

Publications (1)

Publication Number Publication Date
CA2373994A1 true CA2373994A1 (fr) 2000-11-30

Family

ID=27387807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373994A Abandoned CA2373994A1 (fr) 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles

Country Status (9)

Country Link
EP (1) EP1185301A1 (fr)
JP (1) JP2003500368A (fr)
KR (1) KR20070058028A (fr)
AU (1) AU5273200A (fr)
BR (1) BR0010794A (fr)
CA (1) CA2373994A1 (fr)
MX (1) MXPA01011981A (fr)
TW (1) TWI290052B (fr)
WO (1) WO2000071163A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402804B2 (en) 2004-06-02 2016-08-02 CARDINAL HEALTH SWITZERLAND 515 GmbH Injectable formulations of taxanes for cad treatment

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2385989A1 (fr) 1999-09-27 2001-04-05 Andrew Nienstedt Compositions de composes therapeutiques solubles dans le tocol
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
AU2001293177A1 (en) * 2000-09-27 2002-04-08 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2002043765A2 (fr) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Formulations pharmaceutiques contenant du paclitaxel, ses derives et ses sels pharmaceutiquement acceptables
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
FR2820975B1 (fr) * 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
AU2002347541A1 (en) * 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Stable topical formulation of clarithromycin
WO2003053407A1 (fr) * 2001-12-19 2003-07-03 Research Development Foundation Administration de preparations liposomales de composes a base de vitamine e
EP1469860A4 (fr) * 2002-01-24 2005-09-07 Yissum Res Dev Co Combinaison anticancereuse et son utilisation
DK1509256T3 (da) 2002-05-24 2009-11-23 Angiotech Int Ag Præparater og fremgangsmåde til coating af medicinske implantater
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
PT1562941E (pt) 2002-11-07 2010-01-25 Kosan Biosciences Inc Trans-9,10-desidroepotilona c e d, seus análogos e métodos de fabrico dos mesmos
WO2004073692A1 (fr) * 2003-02-18 2004-09-02 Yamashita, Shinji Capsule dure de medicament peu hydrosoluble
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
EP1498120A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Formulation semi-solide pour l'administration orale du taxol
WO2005018607A1 (fr) * 2003-08-20 2005-03-03 Ajinomoto Co., Inc. Preparation medicinale ayant des proprietes de dissolution ameliorees
EP1510206A1 (fr) * 2003-08-29 2005-03-02 Novagali Pharma SA Formulation huileuse auto-émulsifiable pour l'administration de principes actifs peu solubles dans l'eau
AU2004285037B2 (en) * 2003-10-29 2010-07-22 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
KR20060111581A (ko) * 2003-12-19 2006-10-27 쉐링 코포레이션 약제학적 조성물
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP2452670A1 (fr) 2004-10-01 2012-05-16 Ramscor, Inc. Compositions de médicaments à libération prolongée parfaitement implantable
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
AU2006213673A1 (en) * 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
PL1853250T3 (pl) 2005-02-18 2012-03-30 Abraxis Bioscience Llc Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona
US20080128314A1 (en) * 2005-03-14 2008-06-05 Koichi Takeda Pharmaceutical Composition Containing Hardly Water Soluble Medicament
MX2007013494A (es) 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
EA017264B1 (ru) * 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
ES2330898T3 (es) * 2006-03-10 2009-12-16 Laboswiss Ag Procedimiento para la solubilizacion, dispersion y estabilizacion de sustancias, productos preparados de acuerdo con el procedimiento, asi como su uso.
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2008026644A1 (fr) 2006-08-29 2008-03-06 Fujifilm Corporation Matrice hydrophile ayant un composé faiblement soluble dans l'eau scellé à l'intérieur de celle-ci et procédé pour produire celle-ci
WO2008088037A1 (fr) * 2007-01-18 2008-07-24 National University Corporation Chiba University Préparation médicinale à particules fines
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
WO2009084801A1 (fr) * 2007-12-31 2009-07-09 Samyang Corporation Composition micellaire de copolymère à blocs amphiphiles contenant du taxane et son procédé de fabrication
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011019911A1 (fr) * 2009-08-14 2011-02-17 Opko Health, Inc. Formulations intraveineuses d'antagonistes de neurokinine-1
US20110070293A1 (en) 2009-09-23 2011-03-24 Javeri Indu Methods for the Preparation of Liposomes Comprising Docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011060352A1 (fr) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques de ligands de recepteurs de la melanocortine
US20110144578A1 (en) * 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
CN102101863B (zh) 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP5876467B2 (ja) * 2010-03-17 2016-03-02 クローダ，インコーポレイティド ポリマー界面活性剤
KR20130028728A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
WO2011123393A1 (fr) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
NZ604662A (en) * 2010-08-04 2014-08-29 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
DK3238709T3 (da) * 2011-04-28 2020-09-28 Platform Brightworks Two Ltd Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
WO2018005412A1 (fr) * 2016-06-28 2018-01-04 Tien Yang Der Nanogouttelettes chimioprotectrices/chimioactives et leurs procédés d'utilisation
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
EP3424493A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
EP3424494A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
KR102197257B1 (ko) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
KR100239799B1 (ko) * 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ314060A (en) * 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
EP0988858A1 (fr) * 1997-04-18 2000-03-29 Taisho Pharmaceutical Co., Ltd Microemulsion
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402804B2 (en) 2004-06-02 2016-08-02 CARDINAL HEALTH SWITZERLAND 515 GmbH Injectable formulations of taxanes for cad treatment

Also Published As

Publication number Publication date
EP1185301A1 (fr) 2002-03-13
WO2000071163A1 (fr) 2000-11-30
TWI290052B (en) 2007-11-21
MXPA01011981A (es) 2003-09-04
JP2003500368A (ja) 2003-01-07
KR20070058028A (ko) 2007-06-07
AU5273200A (en) 2000-12-12
BR0010794A (pt) 2002-06-04

Similar Documents

Publication Publication Date Title
US6660286B1 (en) Emulsion vehicle for poorly soluble drugs
US7030155B2 (en) Emulsion vehicle for poorly soluble drugs
CA2373994A1 (fr) Excipient en emulsion pour medicaments faiblement solubles
WO1998030205A9 (fr) Excipient emulsionne pour medicaments faiblement solubles
US6245349B1 (en) Drug delivery compositions suitable for intravenous injection
Cannon et al. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery—Part I: parenteral applications
WO2012028101A1 (fr) Compositions liquides de médicaments insolubles et procédés de préparation de celles-ci
EP0999833A1 (fr) Emulsion de taxol
US6858227B1 (en) Vitamin E conjugates
WO2003057193A1 (fr) Compositions de monoterpene et leurs utilisations
WO2002026208A2 (fr) Excipient emulsionne pour medicaments a faible solubilite
KR100754352B1 (ko) 난용성 약물용 에멀젼 부형제의 제조방법
AU2001280084B2 (en) Amphotericin b structured emulsion
AU5731498A (en) Emulsion vehicle for poorly soluble drugs
AU2001280084A1 (en) Amphotericin B structured emulsion
Cannon et al. 10 Emulsions, Microemulsions, and Lipid-Based Drug Delivery Systems for Drug Solubilization and Delivery—Part I: Parenteral Applications
TW201223560A (en) Drug-loaded emulsion and the preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued